Stryker CEO Succession: Spencer Stiles to Replace Kevin Lobo on January 1, 2027, as Lobo Becomes Executive Chair

Stryker (NYSE:SYK) said on 6 October 2026 that President and Chief Operating Officer Spencer Stiles will become Chief Executive Officer on January 1, 2027, succeeding Kevin Lobo, who becomes Executive Chair of the Board the same day. The company announced the change in press release 26-19 and in a Form 8-K under Item 5.02. Both executives signed letter agreements dated October 5, 2026.

Lobo has been CEO since October 2012. Stryker is based in Portage, Michigan.

When does Stryker's CEO change take effect?

The change takes effect on January 1, 2027. According to the 8-K, Lobo will resign as Chief Executive Officer on December 31, 2026, and Stiles takes the role the next day. Stiles is also appointed to the board effective January 1, 2027.

The letters are dated 5 October, one day before the 6 October announcement and 8-K.

Who is Spencer Stiles?

Spencer S. Stiles, 50, is Stryker's President and Chief Operating Officer, a role he has held since January 2026, according to the 8-K. The filing describes a 27-year career at the company. The press release says he joined the Endoscopy business in 1999 and has held leadership roles across Orthopaedics, MedSurg and Neurotechnology.

The 8-K lists a bachelor's degree in business from Miami University and an MBA from the University of Nebraska. In the press release, Stryker says Stiles led the Joint Replacement and Trauma & Extremities businesses and the Digital, Robotics and Enabling Technologies organization as Group President, Orthopaedics. It adds that he had responsibility for international regions and enterprise mergers and acquisitions strategy, and led the Wright Medical acquisition and the separation of the spinal implants business.

The filing states that no arrangement or understanding exists between Stiles and any other person regarding his selection, that he has no family relationship with any director or executive officer, and that he has no transactions requiring disclosure under Item 404(a) of Regulation S-K.

What happens to Kevin Lobo?

Lobo becomes Executive Chair of the Board on January 1, 2027. He joined Stryker in 2011 as Group President, became CEO in October 2012 and was appointed Chair of the Board in July 2014, the company says. So the move changes his title from Chair and CEO to Executive Chair rather than adding a new board seat.

In the press release, Lobo said, "The Board and I have worked closely on a succession plan, and with our strong foundation in place, now is the right time for this leadership transition." Sheri McCoy, Stryker's Lead Independent Director, called the announcement "the culmination of a comprehensive, long-term succession planning process."

Stryker credits Lobo with tripling annual net sales from $8.7 billion in 2012 to more than $26 billion in 2026 and with completing more than 60 acquisitions, including Mako. These are the company's own figures. The release does not say whether the 2026 number is a reported fiscal-year total.

What does Lobo's transition agreement say?

The agreement is a short letter dated October 5, 2026 and signed by McCoy, with Lobo countersigning the same day. It is filed as Exhibit 10.1. Its main terms are:

The letter lists no duties for the Executive Chair role and no end date. It also does not address how Lobo's existing equity awards are treated.

What will Spencer Stiles be paid as CEO?

From January 1, 2027, Stiles's annual base salary rises to $1,320,000 and his annual bonus target rises to 150% of base salary, according to the 8-K. His benefit plan eligibility is unchanged. The filing does not state his current salary, so the size of the increase is not given.

The 8-K also says management will recommend that the independent directors approve a February 2027 grant of stock options and performance stock units (PSUs) under the Long-Term Incentive Plan. The aggregate target grant date fair value is $14,200,000.

The filing says the terms generally match Stryker's annual grants, using the fiscal 2027 forms of option and PSU agreement. Because the grant is a recommendation to the independent directors, it is not yet approved.

How does the executive chair structure compare with the CEO role?

Stryker splits the two jobs at the top. Stiles gets the CEO title and a board seat, and Lobo keeps the chairmanship but not the chief executive duties. On compensation, the two letters point in different directions: Lobo's pay stays flat with no new equity, while Stiles's pay is reset for the larger role.

Why is Stryker making this change?

Stryker describes it as a planned succession. The press release calls it "a planned succession process," and McCoy describes "a comprehensive, long-term succession planning process." Stiles moved from Group President, Orthopaedics to President and COO in January 2026.

The filing and release give no other reason. They do not cite financial results, a dispute or a health matter, and this article does not supply one.

What's still unclear?

Several points are not answered by the filing or the release:

• Length of Lobo's Executive Chair term. Neither the letter nor the 8-K summary sets a term or duties. How long Lobo stays, and what authority sits with him versus Stiles, is not stated.
• Treatment of Lobo's existing equity. The letter bars new awards but is silent on awards already granted.
• Stiles's current pay. The filing gives his new base salary and bonus target but the size of the increase is not stated.
• Board approval of Stiles's grant. The February 2027 award is a recommendation to independent directors, so the final terms could change.
• The $26 billion figure. It is a company statement about 2026 and not a reported fiscal-year result.
• Dates. The agreements are dated 5 October 2026, while the announcement and the 8-K's reported event date are 6 October 2026. This is a sequence of steps, not a conflict.

The weakest point for any reader trying to judge the plan is the missing term for the Executive Chair role. A split between CEO and Executive Chair works only if the boundary is clear, and Stryker has not published one in these documents.

Where does the transition leave the rest of Stryker's leadership?

The 8-K and press release name no other executive changes. Stryker has not stated who will take over Stiles's current President and COO duties, or whether the role will be filled. Stryker describes itself as having products in MedSurg, Neurotechnology and Orthopaedics and says it impacts more than 150 million patients annually, which is the company's own figure.

Stryker's board will have 11 members after Stiles joins, up from 10, and the filing says Stiles has not yet been named to a committee.